tbuckley/cabot-search huggingface dataset:
Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation
Authors: Karl B. Kern, Peter Radsel, Jacob C. Jentzer, David B. Seder, Kwan S. Lee, Kapildeo Lotun, Rajesh Janardhanan, Dion Stub, Chiu-Hsieh Hsu, Marko Noc
Journal: Circulation (2020)

Background: The benefit of emergency coronary angiography after resuscitation from out-of-hospital cardiac arrest is uncertain for patients without ST-segment elevation. The aim of this randomized trial was to evaluate the efficacy and safety of early coronary angiography and to determine the prevalence of acute coronary occlusion in resuscitated patients with out-of-hospital cardiac arrest without ST-segment elevation. Methods: Adult (&gt;18 years) comatose survivors without ST-segment elevation after resuscitation from out-of-hospital cardiac arrest were prospectively randomized in a 1:1 fashion under exception to informed consent regulations to early coronary angiography versus no early coronary angiography in this multicenter study. Early angiography was defined as ≤120 minutes from arrival at the percutaneous coronary intervention–capable facility. The primary end point was a composite of efficacy and safety measures, including efficacy measures of survival to discharge, favorable neurologic status at discharge (Cerebral Performance Category score ≤2), echocardiographic measures of left ventricular ejection fraction &gt;50%, and a normal regional wall motion score of 16 within 24 hours of admission. Adverse events included rearrest, pulmonary edema on chest x-ray, acute renal dysfunction, bleeding requiring transfusion or intervention, hypotension (systolic arterial pressure ≤90 mm Hg), and pneumonia. Secondary end points included the incidence of culprit vessels with acute occlusion. Results: The study was terminated prematurely before enrolling the target number of patients. A total of 99 patients were enrolled from 2015 to 2018, including 75 with initially shockable rhythms. Forty-nine patients were randomized to early coronary angiography. The primary end point of efficacy and safety was not different between the 2 groups (55.1% versus 46.0%; P =0.64). Early coronary angiography was not associated with any significant increase in survival (55.1% versus 48.0%; P =0.55) or adverse events (26.5% versus 26.0%; P =1.00). Early coronary angiography revealed a culprit vessel in 47%, with a total of 14% of patients undergoing early coronary angiography having an acutely occluded culprit coronary artery. Conclusions: This underpowered study, when considered together with previous clinical trials, does not support early coronary angiography for comatose survivors of cardiac arrest without ST elevation. Whether early detection of occluded potential culprit arteries leads to interventions that improve outcomes requires additional study. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02387398.
Prevention of human rabies: a challenge for the European Union and the European Economic Area
Authors: Céline M Gossner, Alexandra Mailles, Inma Aznar, Elina Dimina, Juan E Echevarría, Siri Laura Feruglio, Heidi Lange, Francesco Paolo Maraglino, Patrizia Parodi, Jurijs Perevoscikovs, Yves Van der Stede, Tamás Bakonyi
Journal: Eurosurveillance (2020)

Rabies is enzootic in over one hundred countries worldwide. In the European Union/European Economic Area (EU/EEA), the vast majority of human rabies cases are travellers bitten by dogs in rabies-enzootic countries, mostly in Asia and Africa. Thus, EU/EEA travellers visiting rabies enzootic countries should be aware of the risk of being infected with the rabies virus when having physical contact with mammals. They should consider pre-exposure vaccination following criteria recommended by the World Health Organization and if unvaccinated, immediately seek medical attention in case of bites or scratches from mammals. As the majority of the EU/EEA countries are free from rabies in mammals, elimination of the disease (no enzootic circulation of the virus and low number of imported cases) has been achieved by 2020. However, illegal import of potentially infected animals, mainly dogs, poses a risk to public health and might threaten the elimination goal. Additionally, newly recognised bat lyssaviruses represent a potential emerging threat as the rabies vaccine may not confer protective immunity. To support preparedness activities in EU/EEA countries, guidance for the assessment and the management of the public health risk related to rabies but also other lyssaviruses, should be developed.
An Epigenetic Mechanism Underlying Chromosome 17p Deletion–Driven Tumorigenesis
Authors: Mei Chen, Xuelan Chen, Shujun Li, Xiangyu Pan, Yanqiu Gong, Jianan Zheng, Jing Xu, Chengjian Zhao, Qi Zhang, Shan Zhang, Lu Qi, Zhongwang Wang, Kaidou Shi, Bi-Sen Ding, Zhihong Xue, Lu Chen, Shengyong Yang, Yuan Wang, Ting Niu, Lunzhi Dai, Scott W. Lowe, Chong Chen, Yu Liu
Journal: Cancer Discovery (2020)

Chromosome copy-number variations are a hallmark of cancer. Among them, the prevalent chromosome 17p deletions are associated with poor prognosis and can promote tumorigenesis more than TP53 loss. Here, we use multiple functional genetic strategies and identify a new 17p tumor suppressor gene (TSG), plant homeodomain finger protein 23 (PHF23). Its deficiency impairs B-cell differentiation and promotes immature B-lymphoblastic malignancy. Mechanistically, we demonstrate that PHF23, an H3K4me3 reader, directly binds the SIN3-HDAC complex through its N-terminus and represses its deacetylation activity on H3K27ac. Thus, the PHF23-SIN3-HDAC (PSH) complex coordinates these two major active histone markers for the activation of downstream TSGs and differentiation-related genes. Furthermore, dysregulation of the PSH complex is essential for the development and maintenance of PHF23-deficient and 17p-deleted tumors. Hence, our study reveals a novel epigenetic regulatory mechanism that contributes to the pathology of 17p-deleted cancers and suggests a susceptibility in this disease. SIGNIFICANCE: We identify PHF23, encoding an H3K4me3 reader, as a new TSG on chromosome 17p, which is frequently deleted in human cancers. Mechanistically, PHF23 forms a previously unreported histone-modifying complex, the PSH complex, which regulates gene activation through a synergistic link between H3K4me3 and H3K27ac.This article is highlighted in the In This Issue feature, p. 1.
870P Potential assessment of radiomic PET in the evaluation of cervical cancer treatment
Authors: F. Scalorbi, A. Alessi, G. Centonze, A. Lorenzoni, M. Signorelli, G. Calareso, M. Kirienko, F. Martinelli, G. Bogani, G. Argiroffi, F. Raspagliesi, E. Seregni
Journal: Annals of Oncology (2020)
1370P PD-L1 expression as a predictive biomarker for chemotherapy response in metastatic non-small cell lung cancer (mNSCLC)
Authors: R. Woodford, C.K. Lee, W. Cooper, C. Lewis, T. John, S. Lord, I. Marschner, D. Zhou, J.C-H. Yang
Journal: Annals of Oncology (2020)
Novel biliary drainage of a choledochojejunal anastomotic stenosis using a double-balloon endoscope and forward-viewing endoscopic ultrasound
Authors: Kosuke Maehara, Susumu Hijioka, Taku Sakamoto, Yuta Maruki, Kiichi Tamada, Takuji Okusaka, Yutaka Saito
Journal: Endoscopy (2020)

Balloon-assisted enteroscopy (BAE) is used to drain biliary obstructions caused by choledochojejunal anastomotic stenosis (CJS) after digestive tract reconstruction. Endoscopic ultrasound-guided biliary drainage (EUS-BD) is an alternative when scope insertion to the anastomotic site by BAE is difficult [1] [2] [3] [4]. However, EUS-BD is also difficult in post-left lobectomy patients generally. Here, we report a novel method of internal drainage that combined double-balloon endoscopy (DBE) and forward-viewing EUS for a posterior branch CJS following Roux-en-Y reconstruction.
1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study
Authors: J-Y. Blay, S. Chevret, N. Penel, F. Bertucci, E. Bompas, E. Saada-Bouzid, J-C. Eymard, J-P. Lotz, E. Coquan, R. Schott, P. Soulié, C. Linassier, A. Le Cesne, M. Brahmi, N. Hoog-Labouret, F. Legrand, C. Simon, A. Lamrani-Ghaouti, I.L. Ray-Coquard, C. Massard
Journal: Annals of Oncology (2020)
Ultrasound-enhanced fluorescence imaging and chemotherapy of multidrug-resistant tumors using multifunctional dendrimer/carbon dot nanohybrids
Authors: Dan Li, Lizhou Lin, Yu Fan, Long Liu, Mingwu Shen, Rong Wu, Lianfang Du, Xiangyang Shi
Journal: Bioactive Materials (2020)

Development of innovative nanomedicine enabling enhanced theranostics of multidrug-resistant (MDR) tumors remains to be challenging. Herein, we report the development of a newly designed multifunctional yellow-fluorescent carbon dot (y-CD)/dendrimer nanohybrids as a platform for ultrasound (US)-enhanced fluorescence imaging and chemotherapy of MDR tumors. Generation 5 (G5) poly(amidoamine) dendrimers covalently modified with efflux inhibitor of d-α-tocopheryl polyethylene glycol 1000 succinate (G5-TPGS) were complexed with one-step hydrothermally synthesized y-CDs via electrostatic interaction. The formed [email protected] complexes were then physically loaded with anticancer drug doxorubicin (DOX) to generate ([email protected])-DOX complexes. The developed nanohybrids display a high drug loading efficiency (40.7%), strong y-CD-induced fluorescence emission, and tumor microenvironment pH-preferred DOX release profile. Attributing to the DOX/TPGS dual drug design, the ([email protected])-DOX complexes can overcome the multidrug resistance (MDR) of cancer cells and effectively inhibit the growth of cancer cells and tumors. Furthermore, the introduction of US-targeted microbubble destruction technology was proven to render the complexes with enhanced intracellular uptake and anticancer efficacy in vitro and improved chemotherapeutic efficacy and fluorescence imaging of tumors in vivo due to the produced sonoporation effect. The developed multifunctional dendrimer/CD nanohybrids may represent an advanced design of nanomedicine for US-enhanced theranostics of different types of MDR tumors.
801TiP A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)
Authors: M. Milowsky, N. Davis, C. Fung, S. Johnson, P. Langenstroer, K. Jacobsohn, K. Bylow, D. Kilari
Journal: Annals of Oncology (2020)
694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
Authors: T. Niazi, S. Williams, I.D. Davis, M.R. Stockler, A. Martin, K. Bracken, F. Roncolato, M. McJannett, L. Horvath, S. Sengupta, S. Hughes, R. McDermott, J. Catto, P. Kelly, N. Vapiwala, W.R. Parulekar, S. Morgan, R.A. Rendon, C. Sweeney
Journal: Annals of Oncology (2020)
LBA81 Keeping exhausted T-cells in check in COVID-19
Authors: P. Van Mol, A. Franken, C. Dooms, J. Yserbyt, D. Testelmans, P. Meersseman, G. Hermans, J. Wauters, J. Gunst, K. Nackaerts, J. Vansteenkiste, A. Garg, D. Lambrechts, E. Wauters
Journal: Annals of Oncology (2020)
Helen Salisbury: Plan your emergency
Authors: Helen Salisbury
Journal: BMJ (2020)

When I first read about plans to ask patients to book ahead at emergency departments, I assumed it was a joke: “Hello, 111—I’m thinking of breaking my arm next Tuesday. Can I book an appointment for 2 45 pm?”

But it’s far from a joke. Patients who need to visit the emergency department will be encouraged to phone NHS 111, and the service will advise them when to go.1 Patients may also be advised to self-care or be given an appointment with their GP instead. As ridiculous as it sounds, the idea comes from a genuine attempt to reduce crowding in emergency …
LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)
Authors: D. Doroshow, A.L. Schmidt, Z. Bakouny, S. Bhalla, J.A. Steinharter, D. Tremblay, M.M. Awad, A.J. Kessler, G. Bouchard, M. Evans, F. Busser, B.S. Zimmerman, C.R. Curran, T. Jun, R. Haddad, Q. Qin, P.V. Nuzzo, J. Feld, M.D. Galsky, T.K. Choueiri
Journal: Annals of Oncology (2020)
1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital
Authors: D. García-Illescas, N. Saoudi Gonzalez, O. Mirallas, J. Aguilar-Company, I. Ruiz-Camps, A. Garcia-Alvarez, M.J. Lostes Bardaji, A. Valdivia, D.H. Marmolejo Castaneda, M.A. Rezqallah Aron, D.E. López Valbuena, E. Felip, J. Carles, J. Tabernero
Journal: Annals of Oncology (2020)
355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC)
Authors: N. Turner, K. Jhaveri, K. Kalinsky, S. Loibl, S. Loi, S-A. Im, C. Saura, P. Schmid, J.L. Schutzman, T. Stout, G. Lei, K.E. Hutchinson, E. Thanopoulou, D. Juric
Journal: Annals of Oncology (2020)
Microfluidics: Enhancing the Injectability of High Concentration Drug Formulations Using Core Annular Flows (Adv. Healthcare Mater. 18/2020)
Authors: Vishnu Jayaprakash, Maxime Costalonga, Somayajulu Dhulipala, Kripa K. Varanasi
Journal: Advanced Healthcare Materials (2020)

In article number 2001022 by Kripa K. Varanasi and co-workers, a new methodology to inject highly viscous drug formulations subcutaneously using core annular flows is developed. In such a flow, the viscous formulation is lubricated axially by a less viscous fluid. A 7x reduction in injection force is achieved for the highest viscosity ratio tested. As a practical embodiment, a proof-of-concept double barrel syringe is fabricated, expanding the range of injectable viscosities considerably compared to conventional syringes without a significant increase in price.
301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1
Authors: Y-S. Lu, J. Chiu, M. Airoldi, M. Margeli Vila, J. Ponce Lorenzo, F. Ghaznawi, F. Gaudenzi, A. Ridolfi, I. Lorenzo, M. Ruiz Borrego
Journal: Annals of Oncology (2020)
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes
Authors: Yasunobu Nagata, Ran Zhao, Hassan Awada, Cassandra M. Kerr, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, Hideki Makishima, Tomas Radivoyevitch, Jacob G. Scott, Mikkael A. Sekeres, Brian P. Hobbs, Jaroslaw P. Maciejewski
Journal: Blood (2020)
1554P Can thromboprophylaxis impact PFS in patients with advanced pancreatic cancer? Intermediate results of PaCT study
Authors: M.V. Karamouzis, I. Athanasiadis, G.F. Samelis, C. Vallilas, A. Bokas, A. Nikolaidi, A. Dimitriadou, Z. Kakosaiou, N.F. Pistamaltzian, D. Schizas, A. Papalampros, E. Felekouras, D. Dimitroulis, E. Antoniou, G. Sotiropoulos, P. Papakotoulas
Journal: Annals of Oncology (2020)
Early Gluten Introduction and Celiac Disease in the EAT Study
Authors: Kirsty Logan, Michael R. Perkin, Tom Marrs, Suzana Radulovic, Joanna Craven, Carsten Flohr, Henry T. Bahnson, Gideon Lack
Journal: JAMA Pediatrics (2020)

There are no strategies for the prevention of celiac disease (CD). Current guidelines stating that the age at gluten introduction does not affect the prevalence of CD are based on the results from several randomized clinical trials, but the doses of gluten and timing of its introduction varied.To determine whether early introduction of high-dose gluten lowers the prevalence of CD at age 3 years.The Enquiring About Tolerance (EAT) Study was an open-label randomized clinical trial. A total of 1303 children from the general population in England and Wales were recruited and followed up from November 2, 2009, to July 30, 2012. For the present study, samples were collected from November 1, 2012, to March 31, 2015, and data were analyzed from April 25, 2017, to September 17, 2018.Infants were randomized to consume 6 allergenic foods (peanut, sesame, hen's egg, cow's milk, cod fish, and wheat) in addition to breast milk from age 4 months (early introduction group [EIG]) or to avoid allergenic foods and follow UK infant feeding recommendations of exclusive breastfeeding until approximately age 6 months (standard introduction group [SIG]).Evaluation of CD was an a priori secondary end point of the EAT Study, and at age 3 years, all children with available serum samples were tested for antitransglutaminase type 2 antibodies. Children with antibody levels greater than 20 IU/L were referred to independent gastroenterologists for further investigation.Of the 1004 infants included in the analysis, 514 were male (51.2%). The mean (SD) quantity of gluten consumed between ages 4 and 6 months was 0.49 (1.40) g/wk in the SIG and 2.66 (1.85) g/wk in the EIG (P < .001). Mean (SD) weekly gluten consumption ranged from 0.08 (1.00) g/wk at age 4 months to 0.9 (2.05) g/wk at age 6 months in the SIG vs 1.3 (1.54) g/wk at age 4 months to 4.03 (2.40) g/wk at age 6 months in the EIG. Seven of 516 children from the SIG (1.4%) had a diagnosis of CD confirmed vs none of the 488 children in the EIG (P = .02, risk difference between the groups using the bootstrap, 1.4%; 95% CI, 0.6%-2.6%).In this analysis of infants in the EAT Study, the introduction of gluten from age 4 months was associated with reduced CD prevalence. These results suggest that early high-dose consumption of gluten should be considered as a strategy to prevent CD in future studies.isrctn.org Identifier: ISRCTN14254740.
Oestrogen inhibits salt-dependent hypertension by suppressing GABAergic excitation in magnocellular AVP neurons
Authors: Xiangyan Jin, Woong Bin Kim, Mi-Na Kim, Won Woo Jung, Hyung Kyung Kang, Eun-Hwa Hong, Yoon Sik Kim, Wan Joo Shim, Hee Chul Han, Christopher S Colwell, Young-Beom Kim, Yang In Kim
Journal: Cardiovascular Research (2020)

Abundant evidence indicates that oestrogen (E2) plays a protective role against hypertension. Yet, the mechanism underlying the antihypertensive effect of E2 is poorly understood. In this study, we sought to determine the mechanism through which E2 inhibits salt-dependent hypertension.
Demystifying the estimand framework: a case study using patient-reported outcomes in oncology
Authors: Mallorie H Fiero, Madeline Pe, Chana Weinstock, Bellinda L King-Kallimanis, Scott Komo, Heidi D Klepin, Stacy W Gray, Andrew Bottomley, Paul G Kluetz, Rajeshwari Sridhara
Journal: The Lancet Oncology (2020)
Mobile cardiology during the COVID-19 outbreak
Authors: Adelino F Leite-Moreira, Rui Adão
Journal: Cardiovascular Research (2020)

The digital revolution is everywhere, influencing almost every part of our lives and it is here to stay, redesign, and disrupt.Healthcare is quickly becoming digital, as society is leveraging mobile applications (apps) for consultation, first diagnosis, physical fitness, improving adherence to therapies, obtaining medications, amongst many others. 1In the wake of the coronavirus disease-2019 (COVID-19) pandemic, digitalization waves coupled with the potential of the mobile app improvement technology have protected the world from falling apart.The ability of COVID-19 to quickly spread across every country globally has made the collection of population-scale data, to help tackle the pandemic, extremely challenging. 2Thus, in an effort to aid real-time epidemiology monitoring, Drew et al. 3 have unveiled a free mobile app called the COVID Symptom Study, which collects daily symptoms reports from millions of users in the UK.This app provides a guided interface to report a range of individual demographic data and risk factors and, with continuous use, participants can submit daily updates on symptoms, information on healthcare visits, SARS-CoV-2 testing results, and if they are seeking healthcare support, the level of intervention and associated outcomes. 3his unique prospective population-based study is helping to monitor the community dynamics of COVID-19 and to categorize populations with high symptom outbreaks.Indeed, a recent analysis of this data has shown that there are six distinct 'types' of COVID-19, each distinguished by a particular cluster of symptoms with differing clinical needs, creating a potential predictive tool for the need for respiratory support in severe COVID-19. 4he application of these digital tools for disease surveillance and control allows data collection not only for long-term studies but also for immediate public health use.In line with this, special care should be directed to the cardiovascular system due to the complex interaction with COVID-19. 5Indeed, pre-existing cardiovascular diseases (CVD) have been associated with a worse prognosis and a more severe progression of COVID-19, whereas COVID-19 itself can also induce arrhythmia, cardiac injury, fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation.Due to the unknown long-term consequences, regular cardiovascular risk assessment should be considered also in all patients who survive COVID-19. 6As isolation and quarantine remain the most effective tools to control the outbreak, 5 the use of mobile health (mHealth) technology, a subset of digital
725P Prognostic values of PD-L1 expression and CD8 infiltration phenotype in metastatic and recurrent renal cell carcinoma: An exploratory analysis of the ARCHERY study
Authors: T. Tsuzuki, C. Ohe, T. Osawa, Y. Yasuda, T. Tanaka, S. Anai, K. Yamana, S. Hatakeyama, T. Yoshimoto, Y. Nakagawa, T. Fukuyama, N. Matsubara, G. Kimura, H. Uemura
Journal: Annals of Oncology (2020)
1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
Authors: S.I. Rothschild, A. Zippelius, E.I. Eboulet, S. Savic Prince, D. Betticher, A. Bettini, M. Früh, M. Joerger, C. Britschgi, S. Peters, M.T. Mark, A.F. Ochsenbein, W-D. Janthur, C. Waibel, N. Mach, M. Gonzalez, P.R. Froesch, G. Godar, C. Rusterholz, M. Pless
Journal: Annals of Oncology (2020)
1153TiP A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study
Authors: A.C.J. van Akkooi, P.A. Ascierto, J.C. Becker, P. Nathan, P. Nghiem, U. Ostermeier, P.G. Reimann, F. Hermann
Journal: Annals of Oncology (2020)
1632P Regorafenib is associated with increased skeletal muscle loss in gastrointestinal stromal tumor
Authors: K. Ito, K. Harada, Y. Kawamoto, H. Nakatsumi, S. Nakano, R. Saito, T. Yamamura, S. Yuki, N. Sakamoto, Y. Komatsu
Journal: Annals of Oncology (2020)
21P Urethane-induced lung carcinogenesis in genetically edited C57Bl/6 mice with CHEK2 and GPRC5A heterozygous inactivating mutations
Authors: E. Imyanitov, A. Panchenko, O. Permyakov, M. Maydin, M. Yurova, S. Aleksakhina, O. Averina, P. Sergiev
Journal: Annals of Oncology (2020)
379P Impact of MGMT and ABCB1 single nucleotide polymorphisms on temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma
Authors: M. Jamelot, M. Fontanilles, J. Lequesne, L-F. Pépin, S. Lorivel, C. Alexandru, I. Tennevet, F. Clatot, F. Di Fiore, F. Lamoureux
Journal: Annals of Oncology (2020)
LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
Authors: C. Zhou, L. Wu, Y. Fan, Z. Wang, L. Liu, G. Chen, L. Zhang, D. Huang, S. Cang, Z. Yang, J. Zhou, C. Zhou, B. Li, J. Li, M. Fan, W. Zhang, W. Yang, S. Wang, H. Zhou
Journal: Annals of Oncology (2020)
1107P Clinical outcomes to checkpoint inhibitors in NRAS mutated metastatic melanoma (MM) compared with wild type BRAF/NRAS: An Italian Melanoma Intergroup (IMI) study
Authors: M. Guida, P. Quaglino, J. Pigozzo, M. Gabriele, A.M. Di Giacomo, A.M. Minisini, M.G. Tucci, P. Queirolo, F. Spagnolo, M. Occelli, L. Ridolfi, D. Quaresmini, I. De Risi, S. Strippoli
Journal: Annals of Oncology (2020)